• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤免疫治疗的“特洛伊木马”策略:靶向肿瘤微环境。

The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.

机构信息

School of Biomedical Sciences, CHIRI Biosciences Research Precinct, Curtin University, Perth, WA 6102, Australia.

National Centre for Asbestos Related Diseases, UWA School of Medicine and Pharmacology, Harry Perkins Institute of Medical Research, QEII Medical Centre, Perth, WA, Australia.

出版信息

J Immunol Res. 2014;2014:789069. doi: 10.1155/2014/789069. Epub 2014 May 18.

DOI:10.1155/2014/789069
PMID:24955376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4052171/
Abstract

Most anticancer therapies including immunotherapies are given systemically; yet therapies given directly into tumors may be more effective, particularly those that overcome natural suppressive factors in the tumor microenvironment. The "Trojan Horse" approach of intratumoural delivery aims to promote immune-mediated destruction by inducing microenvironmental changes within the tumour at the same time as avoiding the systemic toxicity that is often associated with more "full frontal" treatments such as transfer of large numbers of laboratory-expanded tumor-specific cytotoxic T lymphocytes or large intravenous doses of cytokine. Numerous studies have demonstrated that intratumoural therapy has the capacity to minimizing local suppression, inducing sufficient "dangerous" tumor cell death to cross-prime strong immune responses, and rending tumor blood vessels amenable to immune cell traffic to induce effector cell changes in secondary lymphoid organs. However, the key to its success is the design of a sound rational approach based on evidence. There is compelling preclinical data for local immunotherapy approaches in tumor immunology. This review summarises how immune events within a tumour can be modified by local approaches, how this can affect systemic antitumor immunity such that distal sites are attacked, and what approaches have been proven most successful so far in animals and patients.

摘要

大多数癌症治疗方法包括免疫疗法都是全身性的;然而,直接给予肿瘤的治疗方法可能更有效,特别是那些克服肿瘤微环境中天然抑制因素的方法。肿瘤内递药的“特洛伊木马”方法旨在通过同时诱导肿瘤内微环境变化来促进免疫介导的破坏,同时避免与更“全面”治疗相关的全身毒性,例如大量实验室扩增的肿瘤特异性细胞毒性 T 淋巴细胞转移或大剂量细胞因子静脉内给药。许多研究表明,肿瘤内治疗具有最小化局部抑制、诱导足够“危险”的肿瘤细胞死亡以交叉引发强烈免疫反应以及使肿瘤血管易于免疫细胞运输以在次级淋巴器官中诱导效应细胞变化的能力。然而,其成功的关键是基于证据制定合理的合理方法。肿瘤免疫学中有大量令人信服的临床前局部免疫治疗方法的数据。这篇综述总结了肿瘤内的免疫事件如何通过局部方法进行修饰,这如何影响全身性抗肿瘤免疫以至于远处部位受到攻击,以及迄今为止在动物和患者中哪些方法最成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/73adbe45a91c/JIR2014-789069.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/22a89be20a25/JIR2014-789069.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/b1e5128a3dfc/JIR2014-789069.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/f518ab7e8788/JIR2014-789069.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/73adbe45a91c/JIR2014-789069.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/22a89be20a25/JIR2014-789069.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/b1e5128a3dfc/JIR2014-789069.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/f518ab7e8788/JIR2014-789069.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec9/4052171/73adbe45a91c/JIR2014-789069.004.jpg

相似文献

1
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.肿瘤免疫治疗的“特洛伊木马”策略:靶向肿瘤微环境。
J Immunol Res. 2014;2014:789069. doi: 10.1155/2014/789069. Epub 2014 May 18.
2
Targeting the tumor microenvironment to enhance antitumor immune responses.靶向肿瘤微环境以增强抗肿瘤免疫反应。
Oncotarget. 2015 Jan 30;6(3):1359-81. doi: 10.18632/oncotarget.3204.
3
Directing Traffic: How to Effectively Drive T Cells into Tumors.引导交通:如何有效地将 T 细胞引导至肿瘤中。
Cancer Discov. 2020 Feb;10(2):185-197. doi: 10.1158/2159-8290.CD-19-0790. Epub 2020 Jan 23.
4
Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.基于过继性细胞疗法和免疫检查点阻断疗法的实体瘤个性化联合免疫疗法的前景。
Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68.
5
Intratumoural immunotherapies in oncology.肿瘤学中的肿瘤内免疫疗法。
Eur J Cancer. 2020 Mar;127:1-11. doi: 10.1016/j.ejca.2019.12.007. Epub 2020 Jan 18.
6
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.优化肿瘤微环境的抗血管生成重编程增强了 CD40 免疫治疗。
Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):541-551. doi: 10.1073/pnas.1902145116. Epub 2019 Dec 30.
7
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.癌症患者对抗癌免疫的抗性:逆转抗性的潜在策略
Ann Oncol. 2017 Mar 1;28(3):457-467. doi: 10.1093/annonc/mdw615.
8
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.免疫肿瘤学:了解免疫系统在癌症中的功能和失调。
Ann Oncol. 2012 Sep;23 Suppl 8(Suppl 8):viii6-9. doi: 10.1093/annonc/mds256.
9
Enhancing tumor T cell infiltration to enable cancer immunotherapy.增强肿瘤 T 细胞浸润以实现癌症免疫治疗。
Immunotherapy. 2019 Feb;11(3):201-213. doi: 10.2217/imt-2018-0111.
10
Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β T Cells and Differentiated γδ T Cells Alongside a Regulatory Response Mediated by FOXP3 T Cells and Immunoregulatory Molecules.在 Oncopig 模型中诱导产生的肿瘤会引发抗肿瘤免疫反应,其中包括细胞毒性 CD8β T 细胞和分化的 γδ T 细胞,同时还伴有 FOXP3 T 细胞和免疫调节分子介导的调节反应。
Front Immunol. 2018 Jun 7;9:1301. doi: 10.3389/fimmu.2018.01301. eCollection 2018.

引用本文的文献

1
Integrated Analysis of Phagocytic and Immunomodulatory Markers in Cervical Cancer Reveals Constellations of Potential Prognostic Relevance.整合分析宫颈癌的吞噬和免疫调节标志物,揭示了具有潜在预后相关性的模式。
Int J Mol Sci. 2024 Aug 22;25(16):9117. doi: 10.3390/ijms25169117.
2
Carborane Conjugates with Ibuprofen, Fenoprofen and Flurbiprofen: Synthesis, Characterization, COX Inhibition Potential and In Vitro Activity.含布洛芬、非诺洛芬和氟比洛芬的碳硼烷共轭物:合成、表征、COX抑制潜力及体外活性
ChemMedChem. 2025 Jan 2;20(1):e202400018. doi: 10.1002/cmdc.202400018. Epub 2024 Nov 8.
3
Prognostic Utility of CD47 in Cancer of the Uterine Cervix and the Sensitivity of Immunohistochemical Scores.

本文引用的文献

1
Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity.抑制 p300 会损害 Foxp3⁺ T 调节性细胞的功能,并促进抗肿瘤免疫。
Nat Med. 2013 Sep;19(9):1173-7. doi: 10.1038/nm.3286. Epub 2013 Aug 18.
2
Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.肺癌的瘤内化疗:重新挑战当前的靶向治疗。
Drug Des Devel Ther. 2013 Jul 18;7:571-83. doi: 10.2147/DDDT.S46393. Print 2013.
3
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
CD47在子宫颈癌中的预后效用及免疫组织化学评分的敏感性
Diagnostics (Basel). 2022 Dec 24;13(1):52. doi: 10.3390/diagnostics13010052.
4
The use of Trojan-horse drug delivery system in managing periodontitis.利用木马药物递送系统治疗牙周炎。
Int Dent J. 2023 Jun;73(3):346-353. doi: 10.1016/j.identj.2022.08.003. Epub 2022 Sep 26.
5
Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy.基于 TNF-α 的木马细菌用于癌症治疗的开发。
Mol Ther. 2022 Jul 6;30(7):2522-2536. doi: 10.1016/j.ymthe.2022.04.008. Epub 2022 Apr 18.
6
How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies.我们对间皮瘤临床前近交系小鼠模型的持续研究如何影响新疗法的开发。
Front Pharmacol. 2022 Mar 31;13:858557. doi: 10.3389/fphar.2022.858557. eCollection 2022.
7
Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.急性髓系白血病中的白血病干细胞特征-用新方法靶向守护者。
Stem Cell Rev Rep. 2022 Jun;18(5):1756-1773. doi: 10.1007/s12015-022-10349-5. Epub 2022 Mar 28.
8
Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions.瘤内注射亚微米颗粒多西他赛联合抗 mCTLA-4 减少了 4T1-Luc 原位种植瘤和转移的肺病变。
Med Oncol. 2021 Jul 31;38(9):106. doi: 10.1007/s12032-021-01555-1.
9
Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.纳米医学与肿瘤免疫疗法:从实验台到病床再到生物标志物
Nanomaterials (Basel). 2020 Jun 29;10(7):1274. doi: 10.3390/nano10071274.
10
Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery.用于免疫治疗以及基因和药物递送的治疗性间充质基质细胞
Mol Ther Methods Clin Dev. 2020 Jan 22;16:204-224. doi: 10.1016/j.omtm.2020.01.005. eCollection 2020 Mar 13.
Fc 依赖性耗竭肿瘤浸润调节性 T 细胞共同定义了抗 CTLA-4 治疗对黑色素瘤的疗效。
J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29.
4
Home sweet home: the tumor microenvironment as a haven for regulatory T cells.温馨的家:肿瘤微环境作为调节性 T 细胞的避风港。
Front Immunol. 2013 Jul 16;4:197. doi: 10.3389/fimmu.2013.00197. eCollection 2013.
5
Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions.肿瘤相关巨噬细胞作为巨噬细胞可塑性、多样性和极化的典范:经验和未解决的问题。
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1478-83. doi: 10.1161/ATVBAHA.113.300168.
6
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.在单一部位耗尽肿瘤特异性 Tregs 可消除播散性肿瘤。
J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.
7
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
8
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.癌症免疫编辑:抗原、机制及对癌症免疫治疗的启示。
Ann N Y Acad Sci. 2013 May;1284(1):1-5. doi: 10.1111/nyas.12105.
9
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.PD-1 和 CTLA-4 的双重阻断联合肿瘤疫苗可有效恢复肿瘤中 T 细胞的排斥功能。
Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.
10
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.CTLA-4 阻断与癌症化疗在诱导抗肿瘤免疫中的协同作用。
PLoS One. 2013 Apr 23;8(4):e61895. doi: 10.1371/journal.pone.0061895. Print 2013.